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GENERAL COMMENTS
This is an original and interesting single center, retrospective observational study aimed at assessing the factors associated with demographic/clinical characteristics and drug selection in ED patients.
The manuscript is well presented in the different parts, introduction , patient and methods , results and discussion Several minor comments: Study limitations section The main problem of the study is that it is a retrospective study and, therefore, no definitive conclusions can be obtained using this study protocol. This is an important point that does not consent to obtain statistically and clinically significant results. Moreover the statement in the study limitation section: "... a retrospective design is the most appropriate design for patients characteristics and selection of drug treatment in patients with ED because face-to-face interviews could cause extreme embarrassment" is questionable. The Authors must comment upon.
Discussion section
In the discussion section the link between ED and BPH are not well explained; the present Reviewer would suggest that this item should be discussed more detailed. The Authors state that "...tamsulosin have been found to have a negative impact on erectile function.." and support this statement citing the famous paper of Carson (Eur Urol 2006) . Honestly this statement is very questionable. The present Reviewer has read back that paper sever times and this statement is not supported in it. On the contrary there are many recent publications asserting exactly the opposite. The Authors must comment upon. The topic of combination therapy (alpha-blocker + PDE-5 inhibitor) in treating lower urinary tract symptoms and sexual dysfunction is not addressed exhaustively. The present reviewer would suggest quoting the article suggesting for the first time that the combined treatment can promote 1) an improvement of both psychometric parameters of both voiding dysfunction (namely, IPSS scores) and erectile dysfunction (namely, IIEF-EF), and 2) a significant amelioration of the There are many publications on this subject that are prospective and with greater power. The only difference is that this is Malaysia but it is retrospective. The presence of clinical data on duration in only 122 of 219 makes me worry about the quality of data in the notes. (The study design was a retrospective in nature, thus duration of ED could not be fully obtained. Nevertheless, no association was made with the parameter "duration of ED").
The ranges of obesity are markedly different from Western ones and the issue of embarrassment in asking about ED is not evidence based as most studies show that men welcome discussions about ED and guidelines suggest routine assessment of ED in virtually all the conditions discussed here.
(The statement pertaining to this comments have been rephrased). Surely gradual or sudden onset is a feature of timing not necessarily related to maintenance of morning erections. I think some of the associations with medications cannot be justified as this is not a controlled study and we do not know why these medications were selected and whether the ED is related to the disorder. There are many papers about drug effects and ED with much better designs. (The retrospective, cross-sectional study design justified the comments and this had also been mentioned in the limitation section) Can we say that 50% of men have BPH which is a pathological diagnosis or do me mean 50% have LUTs as modern theories that that vascular disease, insulin resistance and inflammation cause LUTS independent of prostate size. PDE5Is probably worth through these routes and not directly on the prostate. (References supporting the prevalence of BPH in general and do not specifically associating LUTs and other theories as per the reviewer comments). The comments around alpha blockers and HT really only apply to doxazocin, which is the only licenced alpha blocker for both conditions, so I am not sure how he can conclude that tamsulosin might be given for hypertension. (The statement has been rephrased to exclude hypertension). Tadalafil is only licensed for LUTS/BPH at 5mg daily and it must be conjecture to say that on demand tadalafil and vardenafil were used for this reason especially with such small numbers. (In studies leading up to FDA approval of Cialis for BPH, men who took 5 mg of tadalafil experienced statistically significant improvement in their BPH symptoms compared with men who took a placebo. Among men who had both erectile dysfunction and BPH, those who took 5 mg of tadalafil reported a significant improvement in symptoms of both erectile dysfunction and BPH, while men who took placebo did not )a statement of evidence has been added into the manuscript.
Reviewer: 2 Reviewer Name Giovanni Liguori Institution and Country Department of Urology University of Trieste, Italy Please state any competing interests or state "None declared": none declared This is an original and interesting single center, retrospective observational study aimed at assessing the factors associated with demographic/clinical characteristics and drug selection in ED patients. The manuscript is well presented in the different parts, introduction , patient and methods , results and discussion Several minor comments:
Study limitations section
The main problem of the study is that it is a retrospective study and, therefore, no definitive conclusions can be obtained using this study protocol. This is an important point that does not consent to obtain statistically and clinically significant results. Moreover the statement in the study limitation section: "... a retrospective design is the most appropriate design for patients characteristics and selection of drug treatment in patients with ED because face-to-face interviews could cause extreme embarrassment" is questionable. The Authors must comment upon.
(The statement has been rephrased) Discussion section In the discussion section the link between ED and BPH are not well explained; the present Reviewer would suggest that this item should be discussed more detailed. (The association of BPH and ED has been further discussed -please refer to the manuscript) The Authors state that "...tamsulosin have been found to have a negative impact on erectile function.." and support this statement citing the famous paper of Carson (Eur Urol 2006) . Honestly this statement is very questionable. The present Reviewer has read back that paper sever times and this statement is not supported in it. On the contrary there are many recent publications asserting exactly the opposite. The Authors must comment upon. (The reference for this statement has been corrected i.e. Song (Asian J Androl 2011). The topic of combination therapy (alpha-blocker + PDE-5 inhibitor) in treating lower urinary tract symptoms and sexual dysfunction is not addressed exhaustively. The present reviewer would suggest quoting the article suggesting for the first time that the combined treatment can promote 1) an improvement of both psychometric parameters of both voiding dysfunction (namely, IPSS scores) and erectile dysfunction (namely, IIEF-EF), and 2) a significant amelioration of the Qmax (namely Liguori G et al J Sex Med. 2009; 6:544-552) 
